MARKET

AGIO

AGIO

Agios
NASDAQ

Real-time Quotes | Nasdaq Last Sale

35.07
-2.68
-7.10%
After Hours: 35.07 0 0.00% 16:56 03/27 EDT
OPEN
36.99
PREV CLOSE
37.75
HIGH
37.75
LOW
35.03
VOLUME
719.72K
TURNOVER
--
52 WEEK HIGH
68.89
52 WEEK LOW
27.77
MARKET CAP
2.40B
P/E (TTM)
-5.1061
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AGIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AGIO stock price target is 64.27 with a high estimate of 80.00 and a low estimate of 42.00.

EPS

AGIO News

More
  • Hedge Funds Were Buying Agios Pharmaceuticals Inc (AGIO) Before The Coronavirus
  • Insider Monkey · 1d ago
  • Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb
  • GlobeNewswire · 3d ago
  • Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR Activator
  • GlobeNewswire · 6d ago
  • FDA clears Agios Pharma's IND for AG-946
  • Seeking Alpha - Article · 6d ago

Industry

Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About AGIO

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
More

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.